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Abstract
Background: To determine the direct and indirect costs of outbreaks of acute viral gastroenteritis (AVG) due to
norovirus in closed institutions (hospitals, social health centers or nursing homes) and the community in Catalonia
in 2010–11.
Methods: Information on outbreaks were gathered from the reports made by epidemiological surveillance units.
Direct costs (medical visits, hospital stays, drug treatment, sample processing, transport, diagnostic tests, monitoring
and control of the outbreaks investigated) and indirect costs (lost productivity due to work absenteeism, caregivers
time and working hours lost due to medical visits) were calculated.
Results: Twenty-seven outbreaks affecting 816 people in closed institutions and 74 outbreaks affecting 1,940 people
in the community were detected. The direct and indirect costs of outbreaks were € 131,997.36 (€ 4,888.79 per outbreak)
in closed institutions and € 260,557.16 (€ 3,521.04 per outbreak) in community outbreaks. The cost per case
was € 161.76 in outbreaks in closed institutions and € 134.31 in community outbreaks. The main costs were
surveillance unit monitoring (€ 116,652.93), laboratory diagnoses (€ 119,950.95), transport of samples (€ 69,970.90),
medical visits (€ 25,250.50) and hospitalization (€ 13,400.00).
Conclusions: The cost of outbreaks of acute viral gastroenteritis due to norovirus obtained in this study was influenced
by the number of people affected and the severity of the outbreak, which determined hospitalizations and
work absenteeism. Urgent reporting of outbreaks would allow the implementation of control measures that
could reduce the numbers affected and the duration of the illness and thus the costs derived from them.
Background
Acute viral gastroenteritis (AVG) is a major cause of mor-
bidity in developed countries, with caliciviruses, and espe-
cially norovirus, being the most-frequent causal agents.
In Catalonia, norovirus is responsible for 33.3 % of
outbreaks of gastroenteritis, affecting more than 1,000
people every year although the hospitalization rate is low
[1, 2]. However, there is evidence that hospitalizations
and deaths due to AVG are not very frequent but appear
to be increasing, with 799 to 3,410 admissions attributed
to norovirus in the seasons with the lowest and highest
norovirus activity, respectively in England during the
years 2000 to 2006 [3]. In the United States, sporadic
and outbreak-associated norovirus is estimated to cause
around 800 deaths and 70,000 hospitalizations each year,
increasing during epidemic years associated with emer-
gent strains and with advancing age [4] and, especially,
long term health-care settings [5].
In Catalonia, the number of outbreaks of acute gastro-
enteritis (AG) has gradually declined in recent years
from 222 in 2005 to 111 in 2009, probably because of
the reduction in the number of outbreaks caused by Sal-
monella spp [6]. Likewise, there were 57 outbreaks due
to norovirus in 2005 in comparison to 34 in 2009 yet the
incidence rates of cases associated with outbreaks
remained high (18.4 per 100,000 persons/year in 2005 to
31.7 per 100,000 person years in 2009) [2].
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Studies have estimated the cost of AVG as € 16 million
in Malta, €345 million in the Netherlands and A$ 342.8
million in Australia [7] (€240.13 million). The cost of
outbreaks varies widely from $ 40,675 (€30,178.71) [8] to
£1,200,000 (€1,514,921.67) [9] according to the number
of cases and their severity and according to the different
components measured and the perspective used.
Although AVG has a benign course, it generates a
significant consumption of health resources. To date,
there are no data on the economic impact of AVG in
Catalonia and the resources used by the Public Health
Agency of Catalonia in monitoring and controlling of
outbreaks of AVG is unknown.
The aim of this study was to determine the direct and
indirect costs of outbreaks of AVG due to norovirus in
closed institutions (hospitals, social health centers and
nursing homes) and the community in 2010–2011 in
Catalonia.
Methods
In Catalonia, epidemiological surveillance units (ESU)
of the Public Health Agency of Catalonia are respon-
sible for the control and monitoring of outbreaks of
AVG. When an outbreak is reported to the ESU, moni-
toring, treatment and control of the outbreak is initi-
ated. Stool samples are taken and sent for analysis to
the microbiology laboratory of the Vall d’Hebron hos-
pital in Barcelona.
Acute gastroenteritis was defined as diarrheal disease
of rapid onset often accompanied by nausea, vomiting,
fever, or abdominal pain. Outbreaks of AG were defined
as AG affecting two or more persons who had similar
clinical signs and symptoms, and had the same exposure
to a common source of infection or by person to person
transmission, or were epidemiologically linked. Epi-
demiological surveillance questionnaire is completed to
carry out the investigation of the outbreak. Variables
included in the questionnaires were demographic and
clinical variables of cases such as gender, age, onset and
duration of symptoms, medical consultation and treat-
ment, occupation and need for work leave; as well as
virological information obtained from stool sampling
and analysis at the microbiology laboratory. Stool sam-
ples were taken from patients, workers and food han-
dlers. Stool samples were pre-screened using standard
microbiological tests to rule out bacteria and parasites
and stored at −20 C Enzyme immunoassay (EIA) were
performed on stool specimens. Additionally, reverse
transcriptase-polymerase chain reaction (RT-PCR) de-
tection was performed according to standard guidelines.
Norovirus genotyping was performed by sequencing the
amplimers obtained with the JV12/JV13 pair of primers.
In outbreaks where less than three samples were col-
lected, Kaplan’s criteria were followed [10].
All data collected during the study period was assessed.
Although some data regarding food handlers, such as age,
exposure to suspected food source of infection and previ-
ous AG was not always available it wasn’t considered rele-
vant for the cost analysis.
To determine the cost and resource consumption gen-
erated by types of outbreaks we analyzed outbreaks in
closed institutions (hospitals, nursing homes and social
health centers) and community outbreaks. Community
outbreaks include all other community settings such as
school, restaurants and catering facilities.
Direct costs
Direct costs were those that are closely related to the dis-
ease. We differentiated between direct healthcare and
non-healthcare costs. We calculated the cost of outbreaks
of AVG due to norovirus using information obtained from
the reports made by the ESU from January 1st 2010 to
December 31st 2011 as to the following variables: number
of medical visits, hospital stays, drug treatment, sample
processing, transport, diagnostic tests, monitoring and
control of the outbreaks investigated to calculate direct
costs of the outbreaks
Direct healthcare costs
Including the cost of medical visits, drug treatment and
hospitalizations.
Cost of medical visits
This was calculated by multiplying the number of medical
visits made (patients seen in primary care centers, in hos-
pital emergency rooms, subsequent hospital visits, medical
visits in the institution where the outbreak occurred, and
private medical visits) by the unit cost of each type of visit
(€ 60, €118, € 51, € 30 and €70, respectively). The weighted
mean cost was calculated according to the formula:
Weighted mean ¼
X
wx=
X
w
Σ the sum
w the weights
x the value
And the resulting cost to apply per visit was €61.85
in outbreaks in closed institutions and €56.93 in com-
munity outbreaks. This cost was obtained considering
that patients affected by outbreaks in closed institutions
made a total of 45 visits and those affected by commu-
nity outbreaks made 401 visits.
Cost of drug treatment
We differentiated between the cost of supportive drug
treatment and the cost of antibiotics. The number of pa-
tients receiving each drug prescribed recorded in the
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ESU reports was multiplied by the unit cost (retail price).
Support drugs prescribed were: antipyretics, anti-emetics,
intravenous fluids, and others.
Cost of hospitalization
Hospitalization costs were calculated by multiplying the
number of people admitted to hospital by the number of
hospital days (2.5 days for outbreaks in closed institu-
tions and 2 days in community outbreaks) and by €536
per day of stay.
Direct non-healthcare costs
These included the costs of laboratory diagnosis, ESU
monitoring and control, patient travel expense for med-
ical assistance, and the transport of samples.
Laboratory diagnosis
Bacterial cultures and molecular techniques (RT-PCR)
and were performed for all samples. Both tests were
evaluated using the unit cost of the Vall d’Hebron
hospital (€66.25 for PCR and €46.38 for bacterial
culture).
Cost of epidemiological surveillance unit monitoring and
control
The cost of ESU monitoring and control of outbreaks
was calculated considering the time spent by techni-
cians per outbreak and the cost per hour of the techni-
cians (€ 15.15/hour), was calculated according to the
salary table for level 22–23 civil service employees of the
Generalitat of Catalonia (monthly salary of €2,499.30), and
hours worked (7.30 hours/day, 22 days/month).
Cost of travel of cases
The number of persons who travelled for medical assist-
ance was multiplied by the distance in kilometers for a
round trip and by €0.30/km (travel rate for Government
of Catalonia staff ). Cases in closed institutions travelled
2.7 km, with a cost per case of €0.81, and cases in the
community travelled 6 km, with a cost of €1.81 per case.
Cost of transport of samples
Samples were collected by physicians attending cases
and sent to the reference laboratory at the Hospital Vall
d'Hebron in Barcelona. The cost of transporting a sample
was obtained from the mean cost of immediate special de-
livery courier services in 2010 and 2011, resulting in a cost
of €65.70 per sample in each of type of outbreak.
Calculation of indirect costs
Indirect costs refer to the impact of the disease in patients
regarding work absenteeism, incapacity for normal activ-
ities, such as school absence, and to the time spent by
families caring for patients, and the time used by patients
to attend medical visits. Indirect costs were calculated
with lost productivity due to work absenteeism, caregivers
time and working hours lost due to medical visits.
Work absenteeism
This was calculated using the human capital method,
which considers the value of days lost to absenteeism,
equal to the value of lost productivity. Two elements
were considered: days off work and the gross average
inter-professional salary (€2,037.40 per month in 2011,
representing a cost of €92.60/day).
Cost of time of children aged less than 14 years
The cost of school absence due to AVG in children aged
< 14 was calculated by multiplying the days of absence
by the cost per day according to the 2011 minimum
wage (€ 641.40 per month).
Cost of time of informal caregivers
The ESU reports did not contain information on the num-
ber of days families spent caring for family members af-
fected by AVG. Therefore, we very conservatively attributed
4 h daily to this care. The cost per hour was based on the
minimum wage (€641.40 per month in 2011), and yielded a
cost of €21.25 day.
All costs are expressed in 2011 Euros. The study was
carried out from the perspectives of the society and the
service provider. No discount rate was applied. To deter-
mine the consistency of the estimates used, we made a
sensitivity analysis in which the following variables were
increased or decreased by 25 %: mean salary of care-
givers, time of follow up of AVG outbreak, days of work
or school absence in adults and children, cots of support
treatment, cost of hospitalization, length of hospital stay
and number of diagnostic tests.
Data may be available upon request to the authors.
The authors did not need any authorization to analyse
data originated from outbreaks investigation by public
health epidemiologist. The information on outbreaks
gathered from the reports made by epidemiological sur-
veillance units belongs to our institution (Public Health
Agency of Catalonia).
Results
In 2010–2011, 101 outbreaks of AVG due to norovirus
were investigated in Catalonia, 66 in 2010 and 35 in 2011
(Table 1). Of these, 27 occurred in closed institutions and
74 in the community. A total of 2756 people were af-
fected, 816 in closed institutions (29.6 %, mean of 30.22
people per outbreak; range 2–91) and 1,940 persons in
community outbreaks (70.4 %, mean of 26.22 people per
outbreak; range 3–191). The annual incidence rate was
18.3 per 100,000 population. No immunocompromised
patients were reported.
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We identified, quantified and evaluated resource con-
sumption for the two types of outbreak. Table 2 shows
the cost components evaluated and the unit costs of
each component according to the ESU reports. In cases
where the information was not available, it was esti-
mated according to the specifications listed below.
Table 2 shows the cost components of outbreaks of
AVG due to norovirus in 2010–2011. Those affected by
outbreaks in this period generated 446 medical visits, a
rate of 0.16 visits per year per case. Twelve patients re-
quired a total of 25 hospital days, representing 2.1 days
per admission and 0.166 days per 100,000 population. A
total of 452 (16.4 %) patients required supportive drug
treatment and 0.76 % required antibiotics. A total of
1,065 samples were processed by RT-PCR and culture de-
terminations. These two components were applied to
38.64 % of the patients and were transported by courier
service for laboratory analysis. The cost was calculated
according to the number of samples obtained in each
group (476 in institutionalized patients and 589 in com-
munity outbreaks).
The cost per case of ESU monitoring and control of
outbreaks was €38.12 in institutional outbreaks and
€44.06 in community outbreaks. There were 222 days of
work absenteeism, 231 days of school absenteeism and
227 days of informal care, a rate per case of 0.081, 0.084,
and 0.082, respectively.
The weighted mean cost was €3.00 per patient in out-
breaks in closed institutions and € 3.01 in patients in
community outbreaks. The same procedure was used to
calculate the cost of antibiotics. The antibiotics pre-
scribed were amoxicillin and amoxicillin plus clavulanic
acid). The weighted mean cost obtained was €3.34 per
patient in closed institution outbreaks and € 2.95 per pa-
tient in community outbreaks.
Table 3 shows the cost of outbreaks of AVG due to
norovirus in Catalonia in 2010–2011. Direct costs,
which accounted for 88.50 % of total costs, included
ESU monitoring (€116,652.93; 29.72 %), laboratory
diagnosis (€119,950.95; 30.56 %), transport of samples
(€69,970.90; 17.82 %), medical visits (€25,250.50;
6.43 %) and hospitalization (€13,400.00; 3.41 %). Indir-
ect costs accounted for 11.50 % of total costs and in-
cluded lost productivity due to work absenteeism
(5.24 %) and the cost of time spent on visits 2.56 %.
The direct and indirect costs of outbreaks in closed in-
stitutions were €131,997.36 (33.63 %) and community
outbreaks €260,557.16 (66.37 %). The cost per outbreak
Table 1 Number of outbreaks and cases of acute viral
gastroenteritis due to norovirus according to year. Catalonia,
2010-2011
Year 2010 2011 Total
n (%) n (%)
Number of outbreaks 66 (65.3 %) 35 (34.6 %) 101
Number of cases 1,969 (71.4 %) 787 (38.6 %) 2,756
Mean number of cases per
outbreak
30.6 27.3 27.3
Range 2–191 3–91 2–191
Table 2 Cost of outbreaks of acute viral gastroenteritis due to norovirus by components. Catalonia, 2010–2011
Item Closed institutional setting % Community setting % Weighted mean
cost €
Rates
Number of consultations 45 5.5 401 20.67 56.35/56.65 a 0.16 consultation/case/year
Hospitalizations 2 0.245 10 0.52 536 4.35 admissions/1000 cases/year
Treatment prescribed 267 32.7 185 9.5 3/3.01 a 16.4 % of cases
Antibiotics 4 0.50 17 0.83 3.34/2.95 a 0.76 % of cases
Laboratory diagnosis
Polymerase chain reaction 476 58.13 589 30.36 66.25 38.64 % of cases
Bacteriology culture 476 58.13 589 30.36 46.38 38.64 % of cases
Transport of samples 476 58.13 589 30.36 66.70 38.64 % of cases
Surveillance unit time 76.25 h/outbreak —— € 15.15/h ——— 38.22/44.06 a
Transportation of cases 35 (1.2 Km/displacement) — 409 (3 Km/displacement) —— 0.3 €/Km 0.16 displacement/case
Work absenteeism 80 9.8 142 7.32 € 92.60 0.08 days/case
School absenteeism ——— ——— 231 11.9 21.25 0.084 days/case
Caregiver needs (days) 80 (4 h) 4.9 373 (4 h) 9.6 21.25 0.082 days/case
Transport time 35 displacements
(2 h consultation)
——— 409 displacements/
(2 h consultation)
——— €11.317/h ———
Total number of cases 816 29.6 1,940 70.4 2,756 18.3×103/cases/year
aFirst value corresponds to closed setting and the second to community setting
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in closed institutions and the community was €4,888.79
and € 3521.04, respectively. The cost per case was
€161.76 in outbreaks in closed institutions and €134.31
in community outbreaks (12.7 % lower).
The cost of ESU monitoring and control of outbreaks
was calculated considering the time spent by technicians
per outbreak (76.15 hours/outbreak).
During the study period there were two deaths in eld-
erly people aged 90 and 101 years, respectively, with
AVG, but due to comorbidities, deaths were not attrib-
uted to AVG and therefore the cost per death were not
calculated.
The sensitivity analysis shows that modifying the study
variables produced only small variations in the cost per
outbreak and therefore the results of the analysis for the
base case were consistent (Table 4).
Discussion
In 2010–2011, most outbreaks of AGV due to norovirus
(74 % of outbreaks and 70.4 % of cases) occurred in the
community. However, the cost per outbreak in the com-
munity (€134.31) was 12.7 % lower than the cost of out-
breaks in closed institutions (€161.76), due to the
greater severity, and therefore greater use of resources,
of cases in closed institutions. The proportion of out-
breaks occurring in closed institutions varies between
the 71 % found by Fretz et al. [11] in Switzerland, the
39 % found by Blanton et al. [12] in the United States,
the 72 % observed by Hellard et al. [7] in Australia, and
the 82 % found by Van den Brandhof in Holland [13]. In
Catalonia, the cost of AVG outbreaks in 2010–2011 was
€392,554.52. Direct costs accounted for 88.50 % of the
total: medical visits, days of hospital stay and drug treat-
ment accounted for 10.20 %, laboratory diagnoses for
48.38 % and the ESU for 29.72 %. Indirect costs accounted
for the remaining 11.50 % of the total cost due to lost
productivity from time off work or school of cases. Gauci
et al. [14] found that direct costs accounted for 70.25 % of
the cost of outbreaks of infectious intestinal disease in
Maltese community, while Dalton et al. [15] found direct
costs accounted for 92 % of the total in a study in food
handlers in Denver (Colorado, USA) and Lucioni et al.
[16] found direct costs were 78 % of the total in a study of
the consumption of contaminated food in Puglia (Italy).
Other studies of outbreaks of AVG have found a lower
proportion attributable to direct costs, such as the 18 %
found by Van den Brandhof et al. [13] and the 22 % ob-
served by Hellard et al. [7] with a restriction of normal
activity occurring in 52 % of cases.
When comparing the result obtained in our study in
which the cost per case in the community outbreaks is
of €134,31, with other studies, there is a great variabil-
ity. In the study of Henson et al. [17] "Gastrointestinal
Estimation of the costs of acute illness in British
Columbia, Canada” carried out between June 2002 and
June 2003, the cost per case was 2,170.20 €, while in
the study of Gauci et al. [14] it was 103,52 €. In the
study of Van de Brandhof et al. [13] carried out in
Holland, the cost per case of AVG was of €77 and in
the community study carried out by Hellard et al. [7] in
Australia €14,27. The variability of the results, not tak-
ing into account differences of costs of each health
system and of occupational loss of productivity that can
exist among different countries, is motivated funda-
mentally by the severity of the symptoms and the num-
ber of days lost of work of cases.
In our study, the number of days of lost productivity
was 0.08 days per case, school absenteeism was 0.084 days
per case and days of care were 0.082. Gauci et al. found
similar results: 0.26 days of lost productivity, 0.0784 days
of school absenteeism and 0.0045 days of care [14].
The hospitalization rate in our study was 0.44 %, simi-
lar to the rate reported by Van den Brandhof et al. (0,5 %)
[13] but higher than the rate reported by Hellard et al.
(0.0816 %) [7] and by Henson et al. (0.003 %) [17]. In
contrast, Gauci et al. found that as much as 6.35 % of
cases were hospitalized [14].
Table 3 Cost of outbreaks of acute viral gastroenteritis due to
norovirus. Catalonia, 2010–2011
Closed institutional
setting €
Community
setting €
Total € %
Consultations 2,536 22,714.50 25,250.50 6.43
Treatment 814.50 607.94 1,422.44 0.36
Hospitalization 2,680.00 10,720.00 13,400.00 3.41
Laboratory diagnosis 53,611.88 66,339.07 119,950.95 30.56
Direct healthcare
costs
59,642.38 100,381.51 160,023.89 40.76
Surveillance unit
follow up
31,184.45 85,468.49 116,652.93 29.72
Transportation
of cases
25.20 739.98 765.18 0.19
Transportation
of samples
31,273.38 38,697.52 69,970.90 17.82
Direct non
healthcare costs
62,483.03 124,905.99 187,389.02 47.74
Total direct costs 122,125.41 225,287.50 347,412.91 88.50
School absenteeism 0.00 4,908.75 4,908.75 1.25
Work absenteeism 7,408.00 13,149.20 20,557.20 5.24
Caregivers time 1,700.00 7,926.25 9, 626.25 2.45
Consultation time 763.95 9,285.47 10,049.42 2.56
Total indirect costs 9,871.95 35,269.67 45,141.61 11.50
Direct & indirect
costs
131,997.36 260,557.16 392,554.52 100
Cost/outbreak 4,888.79 3,521.04 3,886.68 ——
Cost/case 161.76 134.31 142.44 ——
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In our study, direct costs included diagnostic tests and
the transport of samples for analysis. These two compo-
nents were applied to 38.64 % of patients, accounting for
48.38 % of the total cost, whereas in other studies diag-
nostic test were prescribed in only 4.46 % [7] and 5.40 %
[14] of cases. Given the high cost of these components
(30.56 % of direct costs on laboratory diagnosis and
17.82 % on transport of samples to the reference labora-
tory for analysis), it seems appropriate to search for
cheaper alternatives such as availability of laboratory
Table 4 Sensitivity analysis
Sensitivity analysis (SA): AVG community outbreaks Sensitivity analysis (SA): AVG outbreaks in closed institutions
BASE CASE: Cost of outbreak €3,521.04; Cost of Case
€134.31
BASE CASE: Cost of outbreak €4,888.79, Cost of case
€161.76
Sensitivity analysis
type
Outbreak cost Variation Case cost Variation Outbreak cost Variation Case cost Variation
Amount € % Amount € % Amount € % Amount € %
Average salary
caregiver: Δ25%
(€ 92. 60)
3,880.69 359.64 10.21 148.03 13.72 10.22 5,100.2 211.41 4.32 168.76 7 4.33
Average salary
caregiver: (€ 0. 00)
3,413.93 −107.11 −3.04 130.22 −4.09 −3.05 4,825.83 −62.96 −1.29 159.68 −2.08 −1.29
ESU Follow up:
∇25 % (€ 57.19)
3,232.34 −288.70 −8.20 123.30 −11.01 −8.20 44,600.08 −288.71 −5.91 152.21 −9.55 −5.90
Follow EUV
outbreak Time:
Δ25% (€ 95.31)
3,808.75 287.71 8.17 145.32 11.01 8.20 5,116.91 228.12 4.67 169.31 7.55 4.67
Days down
children: Δ 25 %
(288.75 days)
3,554.21 33.17 0.94 135.57 1.26 0.94 4,973.12 84.33 1.72 164.55 2.79 1.72
Days off work
adults: Δ25%
(177.5 days)
Low children days:
Δ 25 %
(173.25 days)
3,466.43 −54.61 −1.55 132.22 −2.09 −1.56 4,804.46 −84.33 −1.72 158.97 −2.79 −1.72
Days off work
adults: Δ25%
(106.5 days)
Treatment cost:
Δ25% (€759.9
community &
€1018.12 closed
institutions
outbreaks)
3,523.10 2.06 0.06 134.39 0.08 0.06 4,896.33 7.54 0.15 162.01 0.25 0.15
Stay cost: Δ25%
(€670) children
& adults
3,557.26 36.22 1.03 135.69 1.38 1.03 4,913.61 24.82 0.51 162.58 0.82 0.51
Stay cost: ∇ 25 %
(€402) children $
adults
3,484.83 −36.21 −1.03 132.93 −1.38 −1.03 4,867.31 −21.48 −0.44 161.05 −0.71 −0.44
Days of stay: Δ
25 % (2.5 days)
children& adults
3,557.26 36.22 1.03 135.69 1.38 1.03 4,913.61 24.82 0.51 162.58 0.82 0.51
Days of stay: ∇
25 % (1.75 days)
adults & children
3,502.93 −18.11 −0.51 133.62 −0.69 −0.51 4,863.98 −24.81 −0.51 160.94 −0.82 −0.51
Stay 2 day:Δ100%
(4 days)
3,665.91 144,87 4.11 139.83 5.52 4.11 4,988.05 99.26 2.03 165.05 3.29 2.03
Diagnostic tests:
Δ25% (€736,25)
3,875.90 354.86 10.08 147.84 13.53 10.07 5,674.77 785.98 16.08 187.77 26.01 16.08
Diagnostic tests:
∇25 % (€441,75)
3,166.19 −354.85 −10.08 120.77 −13.54 −10.08 4,102.82 −785.97 −16.08 135.75 −26.01 −16.08
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tests in a wide range of clinical laboratories, not only pub-
lic health facilities.
To reduce the costs it would be convenient that cases
were reported as soon as they are detected, to avoid
growing number of cases. Moreover in closed institu-
tions, strict hygiene and preventive guidelines should be
followed to avoid onset of new cases. Another aspect
that would reduce the cost of outbreaks would be to
concentrate clinical samples for transport and processing
them all together. Although this can cause delay in con-
firmation of the causal agent and could therefore derive
in the appearance of more secondary cases. In this sense
it would be convenient to carry out a cost-effectiveness
study to assess which alternative is more cost saving : to
keep on with the current procedure of sending the sam-
ples when cases are reported or sending them in a more
aggregated manner that would decrease transportation
and processing costs.
We found that the cost of ESU monitoring was
€900.60 per outbreak. Zingg et al. [8] estimated these
costs at $ 1,408 (€1,045.67) per outbreak but did not in-
clude them in their study, arguing that these units
already exist and no extra staff were needed. We in-
cluded these costs in the study on the grounds that the
functioning of the units has an opportunity cost, and if
staff were not monitoring AVG outbreaks they could be
monitoring another public health problem.
Our results show that 2,756 cases of AVG due to nor-
ovirus occurred in Catalonia in 2010–2011 [18]. Taking
the population of Catalonia at this time [19], this repre-
sents a rate of cases associated to outbreaks of 18.3 per
100,000 persons/year . However, the true rate may be
higher, since we only studied reported outbreaks and did
not take into account sporadic cases or non-reported
outbreaks. The rate is slightly lower than those of previ-
ous years ranging from 18.4 per 100,000 persons/year in
2005 to 31.7 per 100,000 persons/year in 2009 [2, 20].
There were two deaths registered in AVG cases during
the study period, yet the cause of death was finally re-
ported as unrelated to AVG disease but instead caused
by pre-existing underlying diseases. Although AVG can
be potentially life-threatening in immunocompromised
patients, the fact that no immunocompromised patients
were reported could explain the low mortality observed
in our study.
As other authors have stated, we cannot rule out the
possibility of unreported deaths due to AVG. Trivedi et al.
in a study of nursing homes in the states of Oregon,
Wisconsin and Pennsylvania in 2009–2010 found that
deaths due to norovirus rose from 41.9 per residence
per year when there were no outbreaks to 53.9 per
residence per year when outbreaks occurred. The au-
thors estimated an overall excess mortality of 11 % in
the study population [21].
The cost per outbreak of AVG due to norovirus in
Catalonia (€3,534.49) was within the lower range of that
found in other studies: $ 40,675 [8] (€30,178.71), $
657,644 [22] (€488,067.81) and £1.2 million (€1.5 mil-
lion) [9]. In these studies, there were a large number of
healthcare workers affected, and it was necessary to
close beds in affected hospitals, a situation that did not
occur in our study.
Limitations to the study include underreporting of
small outbreaks and no reporting of sporadic cases; no
ward closures in long-term care facilities or hospitals
and, in foodborne outbreaks, only on primary and sec-
ondary cases were investigated, no information was
gathered for tertiary person to person spread. Epidemic
outbreaks of any kind, are under a statutory reporting
condition and because norovirus AG is not a notifiable
disease in Spain, as in most countries, outbreaks are the
only feasible tool for research studies. These are all is-
sues that underestimate the economic and disease bur-
den caused by norovirus.
This study is an example of applied research. An ex-
ample on how and why public health activities should be
assessed. Public health performance is evaluated accord-
ing to different outcomes, and the economic aspects are
something that are not assessed as often as they should
be. There is no doubt in considering that the information
that this work brings up is best for those health profes-
sionals that work in outbreak management and surveil-
lance, but it may also be considered informative to
citizenship to learn on how part of their taxes are spent.
In all, economic assessments should be carried out in a
systematic manner to be aware of the economic burden a
public health performance represents and be able to
achieve a more efficient management of outbreaks.
Conclusions
In conclusion, the cost of outbreaks of AVG due to noro-
virus was influenced by the number of cases and the se-
verity of the outbreak, which determined hospitalizations
and work absence. Urgent reporting of outbreaks to the
ESU is essential in order to take rapid action to reduce the
number of cases and the length of the process.
The lack of widespread availability of laboratory con-
firmation RT-PCR technique makes it necessary to
transport case samples from place of outbreak occur-
rence to the public health laboratory. This fact increases
outbreak investigation expense, thus norovirus testing
and confirmation should be more readily available to
microbiology laboratories enhancing detection of spor-
adic cases that are now under detected.
Health education for food handlers and outbreak con-
trol measures (such as hand washing, which has been
shown to reduce episodes by 30 %) [23, 24] should be
stressed in order to reduce the incidence of outbreak-
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related cases and in turn, their cost. Dedicating scarce
resources to a specific intervention means that other ac-
tions, which might be more efficient, are not carried out.
Preventive measures for outbreaks of AVG due to noro-
virus should be intensified, given the health and social
costs they represent.
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